Naphthamides as anticancer agents inhibiting CREB-mediated gene transcription

Case ID:
Web Published:

Value Proposition:

Researchers at Oregon Health & Science University discovered a novel compound that regulates transcription activity of CREB via a novel mechanism of action. Lead optimization resulted in a first in class chemical series that is potent and highly selective. The efficacy of these compounds has been validated in vitro (e.g., breast and lung cancer cell lines) and in vivo, thus, demonstrating proof-of-concept. Regulation of CREB expression with this novel class of compounds acting in under a novel mechanism of action, address an unmet medical need for treatment of cancer.



Cyclic-AMP response element binding protein (CREB) is a transcription factor that regulates gene expression. CREB-dependent gene transcription is activated when CREB interacts with the CREB-binding protein (CBP). Over expression of CREB results in a poor prognosis for the patient, therefore regulation of CREB activity can be used to treat prostate cancer, breast cancer, lung cancer, and acute myeloid leukemia.


Hydroxynapthamide lead prior to optimization

Market Summary:

·         The “targeted cancer drug” market will reach $51B by 2015 (Decision Resources, 2010)

·         33.6% of the breast cancer therapeutic market revenue in 2006 were generated from targeted drugs (Frost & Sullivan, 2008)


Inventor Profile:

Dr. Xiangshu Xiao is an Assistant Professor and Scientist in the Department of Physiology and Pharmacology, and is a member of the Knight Cancer Institute at OHSU. His lab is focusing on the development of novel drugs targeting biomolecular targets.


Patent Status:

Technology 1295 - Patent Published, PCT WO/2010/048302

Technology 1699 - Patent Filed


Licensing Opportunity:

OHSU Technology 1295 and 1699 are available for exclusive licensing.


Relevant Publications:

Xiao X, Li B, Mitton B, Ikeda A, Sakamoto KM. Targeting CREB for Cancer Therapy: Friend or Foe. Current Cancer Drug Targets.2010;10(4):384-91.


Li B, Xiao X. Discovery of a Small-molecule Inhibitor of the KIX-KID Interaction. ChemBioChem. 2009;10(17):2721-24.

Patent Information:
For Information, Contact:
Lisa Lukaesko
Technology Development Manager
Oregon Health & Science University
Xiangshu Xiao
Bingbing Li
Therapeutics - Cancer
© 2021. All Rights Reserved. Powered by Inteum